

Commission Delegated Directive (EU) 2020/1687 of 2 September 2020 amending the Annex to Council Framework Decision 2004/757/JHA as regards the inclusion of the new psychoactive substance N,N-diethyl-2-[[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1H-benzimidazole-1-ethanamine (isotonitazene) in the definition of ‘drug’

- Article 1 Amendment to Framework Decision 2004/757/JHA
- Article 2 Transposition
- Article 3 Entry into force
- Article 4 This Directive is addressed to the Member States in accordance...
Signature

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

- (1) [OJ L 335, 11.11.2004, p. 8.](#)
- (2) Regulation (EC) No 1920/2006 of the European Parliament and of the Council of 12 December 2006 on the European Monitoring Centre for Drugs and Drug Addiction ([OJ L 376, 27.12.2006, p. 1.](#)).
- (3) Deaths have also been reported by Canada (three cases) and the United States (18 cases).
- (4) Directive (EU) 2017/2103 of the European Parliament and of the Council of 15 November 2017 amending Council Framework Decision 2004/757/JHA in order to include new psychoactive substances in the definition of ‘drug’ and repealing Council Decision 2005/387/JHA ([OJ L 305, 21.11.2017, p. 12.](#)).
- (5) [OJ C 369, 17.12.2011, p. 14.](#)